| Craig Raymond Jones, DO | |
|
2825 E Barnett Rd, Medford, OR 97504 | |
| (801) 739-4685 | |
| Not Available |
| Full Name | Craig Raymond Jones |
|---|---|
| Gender | Male |
| Speciality | Anesthesiology |
| Experience | 13 Years |
| Location | 2825 E Barnett Rd, Medford, Oregon |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1043501349 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207L00000X | Anesthesiology | O-1317 (Idaho) | Secondary |
| 207L00000X | Anesthesiology | 390200000X (Oklahoma) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| St Lukes Magic Valley Medical Center | Twin falls, ID | Hospital |
| Black Hills Surgical Hospital Llp | Rapid city, SD | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| St Lukes Clinic Llc | 1052217478 | 297 |
| Black Hills Surgical Hospital Llp | 5496742835 | 68 |
News Archive
A new type of gene-editing tool, CRISPR-Cas13, has shown promise in RNA targeting. Previous studies have shown the tool as a potential treatment method for viral diseases, including coronavirus disease (COVID-19).
RNA editing gives organisms a way to adapt the instructions that their DNA provides for making proteins. Few people would have described RNA editing as a simple process, but a new paper in Nature Communications demonstrates the process as more complex and difficult to predict than previously assumed. The study, done in living fruit flies, discovered two new mechanisms that govern editing in a key neurodevelopmental gene.
Merck reported today that final results from two pivotal Phase III studies of boceprevir, its investigational oral hepatitis C protease inhibitor, demonstrated significantly higher sustained virologic response (SVR) rates in adult patients who previously failed treatment (treatment-failure; HCV RESPOND-2) and in adult patients who were new to treatment for chronic hepatitis C virus (HCV) genotype 1 compared to control, the primary objective of the studies.
The Centers for Disease Control and Prevention (CDC) has received permission from the Food and Drug Administration (FDA) to provide intravenous artesunate for emergency use in the United States for persons with severe malaria.
SurModics, Inc. announced today that it has acquired a portfolio of intellectual property and collaborative drug delivery projects from PR Pharmaceuticals, Inc., a drug delivery company specializing in injectable, biodegradable sustained release formulations.
› Verified 5 days ago
| Entity Name | St Lukes Clinic Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1790718229 PECOS PAC ID: 1052217478 Enrollment ID: O20031208000899 |
News Archive
A new type of gene-editing tool, CRISPR-Cas13, has shown promise in RNA targeting. Previous studies have shown the tool as a potential treatment method for viral diseases, including coronavirus disease (COVID-19).
RNA editing gives organisms a way to adapt the instructions that their DNA provides for making proteins. Few people would have described RNA editing as a simple process, but a new paper in Nature Communications demonstrates the process as more complex and difficult to predict than previously assumed. The study, done in living fruit flies, discovered two new mechanisms that govern editing in a key neurodevelopmental gene.
Merck reported today that final results from two pivotal Phase III studies of boceprevir, its investigational oral hepatitis C protease inhibitor, demonstrated significantly higher sustained virologic response (SVR) rates in adult patients who previously failed treatment (treatment-failure; HCV RESPOND-2) and in adult patients who were new to treatment for chronic hepatitis C virus (HCV) genotype 1 compared to control, the primary objective of the studies.
The Centers for Disease Control and Prevention (CDC) has received permission from the Food and Drug Administration (FDA) to provide intravenous artesunate for emergency use in the United States for persons with severe malaria.
SurModics, Inc. announced today that it has acquired a portfolio of intellectual property and collaborative drug delivery projects from PR Pharmaceuticals, Inc., a drug delivery company specializing in injectable, biodegradable sustained release formulations.
› Verified 5 days ago
| Entity Name | Medstream Anesthesia Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1649616160 PECOS PAC ID: 7416198049 Enrollment ID: O20190702000908 |
News Archive
A new type of gene-editing tool, CRISPR-Cas13, has shown promise in RNA targeting. Previous studies have shown the tool as a potential treatment method for viral diseases, including coronavirus disease (COVID-19).
RNA editing gives organisms a way to adapt the instructions that their DNA provides for making proteins. Few people would have described RNA editing as a simple process, but a new paper in Nature Communications demonstrates the process as more complex and difficult to predict than previously assumed. The study, done in living fruit flies, discovered two new mechanisms that govern editing in a key neurodevelopmental gene.
Merck reported today that final results from two pivotal Phase III studies of boceprevir, its investigational oral hepatitis C protease inhibitor, demonstrated significantly higher sustained virologic response (SVR) rates in adult patients who previously failed treatment (treatment-failure; HCV RESPOND-2) and in adult patients who were new to treatment for chronic hepatitis C virus (HCV) genotype 1 compared to control, the primary objective of the studies.
The Centers for Disease Control and Prevention (CDC) has received permission from the Food and Drug Administration (FDA) to provide intravenous artesunate for emergency use in the United States for persons with severe malaria.
SurModics, Inc. announced today that it has acquired a portfolio of intellectual property and collaborative drug delivery projects from PR Pharmaceuticals, Inc., a drug delivery company specializing in injectable, biodegradable sustained release formulations.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Craig Raymond Jones, DO 842 E Main St, Medford, OR 97504-7134 Ph: (541) 773-7273 | Craig Raymond Jones, DO 2825 E Barnett Rd, Medford, OR 97504 Ph: (801) 739-4685 |
News Archive
A new type of gene-editing tool, CRISPR-Cas13, has shown promise in RNA targeting. Previous studies have shown the tool as a potential treatment method for viral diseases, including coronavirus disease (COVID-19).
RNA editing gives organisms a way to adapt the instructions that their DNA provides for making proteins. Few people would have described RNA editing as a simple process, but a new paper in Nature Communications demonstrates the process as more complex and difficult to predict than previously assumed. The study, done in living fruit flies, discovered two new mechanisms that govern editing in a key neurodevelopmental gene.
Merck reported today that final results from two pivotal Phase III studies of boceprevir, its investigational oral hepatitis C protease inhibitor, demonstrated significantly higher sustained virologic response (SVR) rates in adult patients who previously failed treatment (treatment-failure; HCV RESPOND-2) and in adult patients who were new to treatment for chronic hepatitis C virus (HCV) genotype 1 compared to control, the primary objective of the studies.
The Centers for Disease Control and Prevention (CDC) has received permission from the Food and Drug Administration (FDA) to provide intravenous artesunate for emergency use in the United States for persons with severe malaria.
SurModics, Inc. announced today that it has acquired a portfolio of intellectual property and collaborative drug delivery projects from PR Pharmaceuticals, Inc., a drug delivery company specializing in injectable, biodegradable sustained release formulations.
› Verified 5 days ago
Dr. Andrew T Young, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 1093 Royal Ct, Medford, OR 97504 Phone: 541-773-7273 Fax: 541-773-2027 | |
Brett T Quave, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 701 Golf View Dr, Medford, OR 97504 Phone: 541-494-1111 Fax: 541-494-1099 | |
Robert Joseph Trujillo, MD Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 842 E Main St, Medford, OR 97504 Phone: 541-733-7273 Fax: 541-733-2027 | |
Theodore John Mcgill, MD Anesthesiology Medicare: Medicare Enrolled Practice Location: 842 E Main St, Medford, OR 97504 Phone: 541-773-7273 Fax: 541-773-2027 | |
Dr. David Lawrence Chandler, D.O. Anesthesiology Medicare: Medicare Enrolled Practice Location: 1093 Royal Ct, Medford, OR 97504 Phone: 541-773-7273 Fax: 541-773-2027 | |
Gregory Wilson Price, D.O. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 1093 Royal Ct, Medford, OR 97504 Phone: 541-773-7273 Fax: 541-773-2027 |